Press Releases NanoViricides, Inc.

Equities

NNVC

US6300873022

Market Closed - Nyse Other stock markets 21:00:00 08/05/2024 BST			5-day change	1st Jan Change
2.03 ^USD	+20.83%		+69.17%	+99.02%

05-08	NanoViricides, Inc. Announces Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox	CI
05-06	NanoViricides, Inc. Announces Novel Broad-Spectrum Antiviral with Activity Against Influenza A	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon	05-01	AQ
NanoViricides: Fiscal Q2 Earnings Snapshot	02-14	AQ
Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications beyond COVID Treatment, Explains NanoViricides, NV-387 Could be As Revolutionary as Antibiotics	02-02	AQ
Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides	01-30	AQ
NanoViricides updates progress on Phase 1a/1b clinical trial of antiviral drug candidate NV-387	11-29	AQ
NanoViricides Has Filed its Quarterly Report, NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications	11-16	AQ
NanoViricides, Inc. - Broad-Spectrum Antiviral NV-387 in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development	11-15	AQ
NanoViricides: Fiscal Q1 Earnings Snapshot	11-15	AQ
NanoViricides, Inc. Has Filed its Annual Report	17/10/23	AQ
Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant	27/09/23	AQ
NanoViricides progressing well with new Covid study	31/08/23	AQ
The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company's Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides	22/08/23	AQ
SARS-CoV-2 Is Not Done Yet Ã¢€” Could This New Drug In Clinical Trials Be The Safest Option For Treating COVID-19?	19/07/23	AQ
NanoViricides testing oral gummy and syrup Covid-19 treatment - Proactive Research Analyst	13/07/23	AQ
Company's Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides	12/07/23	AQ
Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials Ã¢€“ What Other Viruses Could This COVID Treatment Target?	11/07/23	AQ
NanoViricides Inc. (NYSE American: NNVC) Begins Long-Awaited Clinical Trials For Its Anti-Viral Nanomedicine NV-CoV-2, Oral, Amid Continuing Need For COVID Treatment	06/07/23	AQ
NanoViricides take big step forward beginning trials on its antiviral drug NV-CoV-2	29/06/23	AQ
NanoViricides, Inc.	29/06/23	AQ
NANOVIRICIDES, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	25/05/23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases NanoViricides, Inc.

Equities

NNVC

US6300873022

Press Releases

Filters